While it is well established that most prostate tumors express telomerase, more detailed data from a histologic study, reported in the December 15th issue of Cancer, suggest that telomerase immunostaining may be useful in the diagnosis and treatment of prostate cancer.
Dr. Kenneth A. Iczkowski, an assistant professor of pathology at the University of Florida in Gainesville, and colleagues immunostained 62 prostate tumor sections with an antibody to telomerase reverse transcriptase (TERT), the catalytic component of telomerase. Altogether, 28 sections were from low- to intermediate-grade tumors, Gleason score 3 to 6, and 34 were from high-grade tumors, Gleason score 7 to 10.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!